Pelvic lymphadenectomy (PL) provides extremely valuable staging information
in patients being treated for adenocarcinoma of the prostate; however, the
cost and potential morbidity associated with this procedure suggests that
it is not indicated in all patients. This article reviews the indications f
or lymphadenectomy as well as factors that may influence how one chooses wh
ich patients will benefit most from PL. This article provides the initial s
teps for a decision analysis framework that will introduce health state uti
lities into the decision to perform PL on an individual patient basis.